A Randomized, Controlled, Parallel Group, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Ad5FGF-4 Using SPECT Myocardial Perfusion Imaging in Patients With Stable Angina Pectoris.

Trial Profile

A Randomized, Controlled, Parallel Group, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Ad5FGF-4 Using SPECT Myocardial Perfusion Imaging in Patients With Stable Angina Pectoris.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 15 Jun 2016

At a glance

  • Drugs Alferminogene-tadenovec (Primary)
  • Indications Angina pectoris
  • Focus Registrational; Therapeutic Use
  • Acronyms ASPIRE
  • Sponsors Taxus Cardium Pharmaceuticals Group
  • Most Recent Events

    • 09 Jun 2016 Status changed from active, no longer recruiting to discontinued.
    • 26 Jan 2016 Planned End Date changed from 1 Jul 2016 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
    • 26 Jan 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Nov 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top